Christine Motzkus

Christine Motzkus

Auto-generated profile, based on publicly available information

Christine Motzkus

Clinical and Population Health Research Program, University of Massachusetts Medical School, Worcester, MA, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Chest
Verified
Journal Article
Closed access
CLCraig M. Lilly
Craig M. Lilly
CMChristine Motzkus
Christine Motzkus
TRTeresa Rincon
Teresa Rincon
SCShawn E. Cody
Shawn E. Cody
KLKaren Landry
Karen Landry
RIRichard S. Irwin
Richard S. Irwin

22 March 2012 in Gut
Verified
Journal Article
Closed access
PDF file
CMChristine Anne Motzkus-Feagans
Christine Anne Motzkus-Feagans
APAmy Pakyz
Amy Pakyz
RPRonald Polk
Ronald Polk
GGGiovanni Gambassi
Giovanni Gambassi
KLKate L Lapane
Kate L Lapane
Objectives: To estimate the possible relationship between statin use and the risk of healthcare facility onset Clostridium difficile. Methods: Patients over 18 years of age admitted to hospitals contributing data to the University HealthSystem Consortium between 2002 and 2009 were eligible. Patients with the ICD-9-CM code 008.45 who received a minimum 3-day course of either metronidazole or oral vancomycin on/after day 5 of admission were considered incident cases of C difficile infection. 31 472 incident cases of C difficile infection were identified and matched to five controls, on hospital, year/quarter of admission date, and age ±10 years (N=78 096). Patients who were administered one drug in the statin class (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin or simvastatin) before the index date were considered to be exposed. Conditional logistic regression modelling provided adjusted odds ratios and 95% CI. Results: Compared with non-users, users of any drug within the statin class were 0.78 times less likely to develop C difficile infection in the hospital (95% CI 0.75 to 0.81) adjusting for potential confounders. Differences in estimates for specific statins were minimal. Niacin, fibrates and selective cholesterol absorption inhibitors showed no association with the risk of C difficile infection. Conclusions: Our data were consistent with a growing body of literature demonstrating a reduced risk of infections with statin use. Statins' pleiotropic properties may provide protection against C difficile infection.

29 July 2013 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
CMC. Motzkus-Feagans
C. Motzkus-Feagans
APA. L. Pakyz
A. L. Pakyz
SRS. M. Ratliff
S. M. Ratliff
JBJ. S. Bajaj
J. S. Bajaj
KLKate L L Lapane
Kate L L Lapane
Background Evidence about the beneficial effects of statins on reducing infections is accumulating. Identifying ways to reduce infection risk in patients with cirrhosis is important because of increased mortality risk and costs associated with infections. Aim To estimate the extent to which statin use prolongs time to infection among patients with cirrhosis. Methods We identified Veterans with cirrhosis, but without decompensation (n = 19 379) using US Veterans Health Administration data from 2001 to 2009. New users of statins were identified and propensity matched to non-users and users of other cholesterol-lowering medications (1:1 matching). The cohort was followed up for hospitalisations with infections. Cox regression models with time-varying exposures provided estimates of adjusted hazard ratios (HR) and 95% confidence intervals (CI). Results New statin use was present among 13% of VA patients with cirrhosis without decompensation. Overall, 12.4% of patients developed a serious infection, and 0.1% of patients died. In the propensity-matched sample, statin users experienced hospitalisations with infections at a rate 0.67 less than non-users (95% Confidence Interval: 0.47–0.95). Conclusions Infections are a major concern among cirrhotic patients and have the potential to seriously impact both life expectancy and quality of life. Statin use may potentially reduce the risk of infections among patients with cirrhosis.

14 February 2016 in Journal of Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
CMChristine A. Motzkus
Christine A. Motzkus
RLRoger Luckmann
Roger Luckmann
Purpose: Sepsis treatment protocols emphasize source control with empiric antibiotics and fluid resuscitation. Previous reviews have examined the impact of infection site and specific pathogens on mortality from sepsis; however, no recent review has addressed the infection site. This review focuses on the impact of infection site on hospital mortality among patients with sepsis. Methods: The PubMed database was searched for articles from 2001 to 2014. Studies were eligible if they included (1) one or more statistical models with hospital mortality as the outcome and considered infection site for inclusion in the model and (2) adult patients with sepsis, severe sepsis, or septic shock. Data abstracted included stage of sepsis, infection site, and raw and adjusted effect estimates. Nineteen studies were included. Infection sites most studied included respiratory (n = 19), abdominal (n = 19), genitourinary (n = 18), and skin and soft tissue infections (n = 11). Several studies found a statistically significant lower mortality risk for genitourinary infections on hospital mortality when compared to respiratory infections. Conclusion: Based on studies included in this review, the impact of infection site in patients with sepsis on hospital mortality could not be reliably estimated. Misclassification among infections and disease states remains a serious possibility in studies on this topic.

15 November 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CMChristine Motzkus
Christine Motzkus
RWRacquel J Wells
Racquel J Wells
XWXingyue Wang
Xingyue Wang
SCSonia Chimienti
Sonia Chimienti
DPDeborah Plummer
Deborah Plummer
SCSuzanne Cashman
Suzanne Cashman
Implicit bias affects health professionals’ clinical decision-making; nevertheless, published reports of medical education curricula exploring this concept have been limited. This research documents a recent approach to teaching implicit bias. Medical students matriculating during 2014 and 2015 participated in a determinants of health course including instruction about implicit bias. Each submitted a reflective essay discussing implicit bias, the experience of taking the Implicit Association Test (IAT), and other course content. Using grounded theory methodology, student essays that discussed reactions to the IAT were analyzed for content themes based on specific statements mapping to each theme. Twenty-five percent of essays underwent a second review to calculate agreement between raters regarding identification of statements mapping to themes. Of 250 essays, three-quarters discussed students’ results on the IAT. Theme comments related to: a) experience taking the IAT, b) bias in medicine, and c) prescriptive comments. Most of the comments (84%) related to students’ acknowledging the importance of recognizing implicit bias. More than one-half (60%) noted that bias affects clinical decision-making, and one-fifth (19%) stated that they believe it is the physician’s responsibility to advocate for dismantling bias. Through taking the IAT and developing an understanding of implicit bias, medical students can gain insight into the effect it may have on clinical decision-making. Having pre-clinical medical students explore implicit bias through the IAT can lay a foundation for discussing this very human tendency.

1 May 2017 in Chest
Verified
Journal Article
Closed access
CMChristine A. Motzkus
Christine A. Motzkus
CLCraig M. Lilly
Craig M. Lilly